Related Stories
Drug Companies Drive the Psychiatric Drugging of Children
Key Excerpts from Article on Website of Huffington Post
Posted: July 17th, 2017
http://www.huffingtonpost.com/dr-peter-breggin/psychiatric-d...
Johnson & Johnson, the company that makes the antipsychotic drug Risperdal, has tentatively agreed to a settlement of $2.2 billion to resolve a federal investigation into the companys marketing practices. Johnson & Johnson confidentially paid psychiatrists such as Harvards Joseph Biederman to promote adult drugs such as the powerful antipsychotic drug Risperdal for children. The company has even ghost-written at least one of the Harvard professors scientific articles. Another recent DOJ settlement with drug company GlaxoSmithKline resulted in Glaxos agreement to pay $3 billion in criminal and civil fines. GlaxoSmithKline employed several tactics aimed at promoting the use of [Paxil] in children, including helping to publish a medical journal article that misreported data from a clinical trial. GlaxoSmithKline also secretly paid about $500,000 to psychiatrist Charles Nemeroff ... to promote Paxil. Glaxo even ghostwrote a psychopharmacology textbook for family doctors, who write many prescriptions for children, which was coauthored by Nemeroff and psychiatrist Alan Schatzberg. None of these drug-company-bought psychiatrists has suffered serious consequences. Meanwhile, the DOJ has now enforced a total of $8.9 billion in criminal and civil fines against GlaxoSmithKline, Pfizer, Eli Lilly, and Johnson & Johnson. Stimulants, antidepressants and antipsychotic drugs are very harmful to the brain. The health professions would do far more good stopping the drugging of children than continuing or increasing it.
Note: The above was written by Peter Breggin, MD, author of the book, "Psychiatric Drug Withdrawal: A Guide for Prescribers, Therapists, Patients and Their Families" For more along these lines, see concise summaries of deeply revealing Big Pharma corruption news articles from reliable major media sources.